Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. The company also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels. Its advanced preclinical product candidate is ONS-1050, a trastuzumab biosimilar, interferes with the human epidermal growth factor receptor 2, a protein that stimulates cell proliferation. Oncobiologics, Inc. has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone609-619-3990
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.81 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Oncobiologics (NASDAQ:ONS) Frequently Asked Questions
What is Oncobiologics' stock symbol?
Oncobiologics trades on the NASDAQ under the ticker symbol "ONS."
Has Oncobiologics been receiving favorable news coverage?
News headlines about ONS stock have been trending somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Oncobiologics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Oncobiologics' key competitors?
Some companies that are related to Oncobiologics include Jounce Therapeutics (JNCE), Novavax (NVAX), La Jolla Pharmaceutical (LJPC), ADMA Biologics (ADMA), Compugen (CGEN), Neon Therapeutics (NTGN), Erytech Pharma (ERYP), Allena Pharmaceuticals (ALNA), Surface Oncology (SURF), Organovo (ONVO), Champions Oncology (CSBR), Pluristem Therapeutics (PSTI), Fennec Pharmaceuticals (FENC), Nantkwest (NK) and Outlook Therapeutics (OTLK).
What other stocks do shareholders of Oncobiologics own?
Who are Oncobiologics' key executives?
Oncobiologics' management team includes the folowing people:
- Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Principal Accounting Officer, Company Sec.,Treasurer & Director (Age 52)
- Dr. Pankaj Mohan, Founder & Director (Age 53)
- Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 65)
- Mr. Ralph H. Thurman, Exec. Chairman (Age 69)
- Rick Gregory, Director of Marketing & Communications
When did Oncobiologics IPO?
(ONS) raised $35 million in an initial public offering (IPO) on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.
How do I buy shares of Oncobiologics?
Shares of ONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Oncobiologics?
Oncobiologics has a market capitalization of $0.00 and generates $3.81 million in revenue each year.
What is Oncobiologics' official website?
How can I contact Oncobiologics?
Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]
MarketBeat Community Rating for Oncobiologics (NASDAQ ONS)
MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe ONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
